Don't miss AstraZeneca's interactive scientific exchange symposium at ECIO 2025 on the evolving treatment landscape of embolisation-eligible HCC, chaired by Dr Laura Crocetti! Join us for valuable insights on multimodal treatment combinations, remaining unmet needs, treatment goals and future outlook in embolisation‑eligible HCC as well as participation in an engaging panel discussion with our expert faculty. Advancing patient care for embolisation-eligible HCC: emerging treatments and future outlook Sunday, 13th April, 12:30–⁠13:15 CEST Auditorium 2, Rotterdam Ahoy Convention Centre, Rotterdam, Netherlands Faculty: Laura Crocetti, MD, PhD Italy David Pinato, MD, PhD UK Gianluca Masi, MD Italy 12:30–12:35 Welcome and introductions Laura Crocetti 12:35–12:45 Plenary: Unmet needs in the management of embolisation-eligible HCC: focusing on treatment goals and patient priorities Laura Crocetti 12:45–12:55 Plenary: Scientific rationale and clinical evidence for multimodal treatment in embolisation-eligible HCC David Pinato 12:55–13:05 Panel discussion: How can we enhance MDT coordination and improve outcomes for people with embolisation-eligible HCC? Gianluca Masi All faculty participation Audience participation through polling 13:05–13:15 Audience Q&A All faculty Audience participation We look forward to seeing you in Rotterdam! This non-promotional scientific exchange symposium has been organised and funded by AstraZeneca for healthcare professionals only. During this symposium, data may refer to medicines or indications under investigation or that may not be approved in your country. The information should under no circumstances be regarded as a recommendation for use of the medicine or indication. Please consult your local prescribing information. Veeva ID: NL-15480 Date of preparation: March 2025